drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Lentivirally transduced CAR T cells recognizing EBV latent membrane protein 1 (LMP1); IV infusion with dose escalation; targets LMP1-expressing EBV-associated malignancies through CAR-triggered cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
T cells are lentivirally engineered to express a chimeric antigen receptor that recognizes EBV latent membrane protein 1 (LMP1). CAR engagement of LMP1 on tumor cells triggers MHC-independent T-cell activation, leading to perforin/granzyme-mediated cytotoxicity and cytokine-driven tumor clearance in EBV-associated malignancies.
drug_name
LMP1-directed CAR T cells
nct_id_drug_ref
NCT06849921